Keith S. Bahjat, Ph.D.
Affiliations: | 2001 | University of Florida, Gainesville, Gainesville, FL, United States |
Area:
ImmunologyGoogle:
"Keith Bahjat"Parents
Sign in to add mentor| Michael J. Clare-Salzler | grad student | 2001 | UF Gainesville | |
| (Dendritic cell development and distribution in Type I diabetes: Overcoming genetic defects and establishing tolerance via pharmacotherapeutic manipulation of dendritic cell population in vivo.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Johnston RJ, Su LJ, Pinckney J, et al. (2019) VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 574: 565-570 |
| Zebertavage L, Bambina S, Shugart J, et al. (2019) A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity. Plos One. 14: e0209153 |
| Alice AF, Kramer G, Bambina S, et al. (2017) Amplifying IFN-γ Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity. Journal of Immunology (Baltimore, Md. : 1950) |
| Kuai R, Ochyl LJ, Bahjat KS, et al. (2016) Designer vaccine nanodiscs for personalized cancer immunotherapy. Nature Materials |
| Koguchi Y, Hoen HM, Bambina SA, et al. (2015) Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab. Cancer Research. 75: 5084-92 |
| Baird JR, Friedman D, Cottam B, et al. (2015) Radiation therapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Research |
| Hannani D, Vétizou M, Enot D, et al. (2015) Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 25: 399-400 |
| Hannani D, Vétizou M, Enot D, et al. (2015) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 25: 208-24 |
| Crittenden M, Bahjat KS, Li R, et al. (2015) Phase I study of safety and immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas. Journal of Clinical Oncology. 33 |
| Uhde L, Bambina S, Alice A, et al. (2015) Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma Journal For Immunotherapy of Cancer. 3: 78 |